Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moxi-Well-C is a veterinary antibiotic combination developed by Pure Med Farma, typically containing amoxicillin sodium and cloxacillin sodium. It is marketed as a generic injectable product, often in a 5000 mg (5g) vial presentation, for the treatment of bacterial infections in livestock such as cattle and goats. Amoxicillin is a broad-spectrum penicillin that inhibits bacterial cell wall synthesis, while cloxacillin is a penicillinase-resistant penicillin that provides additional coverage against beta-lactamase-producing Staphylococci. The combination is primarily indicated for conditions such as mastitis, respiratory tract infections, metritis, and other systemic bacterial diseases in veterinary medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + cloxacillin (42cd4f).